Products

Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
ActiveMax® Recombinant Mouse VEGF164 (HPLC-verified), 20µg  

ActiveMax® Recombinant Mouse VEGF164 (HPLC-verified), 20µg

ActiveMax® Recombinant Mouse VEGF164 Protein, Ala 27 - Arg 190 was produced in human 293 cells (HEK293), Tag free (HPLC-verified)

Synonym: recombinant human protein, VEGF164, VEGFA, VPF

More details

VE4-M4216-20

Availability: within 7 days

238,00 €

Background
Vascular endothelial growth factor A (VEGFA) is also known as Vascular permeability factor (VPF). VEGFA belongs to the PDGF/VEGF growth factor family. VEGFA is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis and endothelial cell growth, promoting cell migration, and inhibiting apoptosis. Alternatively spliced transcript variants, encoding either freely secreted or cell-associated isoforms, have been characterized. VEGFA is produced by a group of three major isoforms as a result of alternative splicing and if any three isoforms are produced (VEGFA120, VEGFA164, and VEGFA188) then this will not result in vessel defects and death of the full VEGFA knockout in mice.

Source
ActiveMax® Recombinant Mouse VEGF164, Tag Free (HPLC-verified) (VE4-M4216) is expressed from human 293 cells (HEK293). It contains AA Ala 27 - Arg 190 (Accession # AAB22253.1 ).
Predicted N-terminus: Ala 27

Molecular Characterization
This protein carries no "tag".
The protein has a calculated MW of 19.3 kDa. The protein migrates as 23-30 kDa under reducing (R) condition (SDS-PAGE) due to different glycosylation.

Endotoxin
Less than 1.0 EU per μg of the mouse VEGF164 by the LAL method.

Purity
>95% as determined by SDS-PAGE.
>95% as determined by SEC-HPLC.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally Mannitol or Trehalose are added as protectants before lyophilization.
Contact us for customized product format or formulation.

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Storage
Avoid repeated freeze-thaw cycles.
No activity loss was observed after storage at:
In lyophilized state for 1 year (4oC); After reconstitution under sterile conditions for 3 months (-70oC). 

Bioactivity
Please refer to product data sheet.

References

(1) Shin S.-Y., et al., 2005, Yonsei Med. J. 46:679-686.
(2) Breier G., et al., 1992, Development 114:521-532.

The following products could also be interesting for you: